Physicians want better labeling of biosimilars
European physicians want more information in the biosimilar label than is currently available, according to a new study initiated and supported by EuropaBio.
When comparing a standard label of an authorized biosimilar with a label containing additional relevant information, 83% of physicians preferred the one with additional information about what data had been generated with which product, according to a press release. In addition, 91% said that they use the label frequently or occasionally as a source of information and 87% said it was helpful, or very helpful, to include a clear statement on the origin of the biosimilar’s data on the label (Healthcare Packaging, 19 April 2016).
Click here for the original news item.
Click here for the research article in Regular Toxicology and Pharmacology.
Click here for more information about the module Pharmaceutical packaging regulations of the NVC E-Course Pharmaceutical Packaging.
If you have any questions about this subject, please contact us: email@example.com, +31-(0)182-512411. This item is also included in our monthly overview, the NVC Members-only Update.